A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura - Jilma-Stohlawetz, P; Gilbert, J C; Gorczyca, M E; Knöbl, P; Jilma, B (Thromb Haemost, 2011)